
|Articles|April 22, 2011
Increased Demand Causes Fuji to Expand Astaxanthin Production
The plan is to double current production capacity.
Advertisement
Fuji Chemical Industry Company, Ltd., (Toyama, Japan) announced plans to double production of its AstaReal natural astaxanthin (Haematococcus pluavialis) in response to increased demand worldwide, the company says. Production will ramp up at Fuji’s wholly owned subsidiary BioReal AB in Gustavsberg, Sweden.
The company says demand has been driven by increasing science supporting AstaReal’s “positive effects on health,” along with AstaReal’s GRAS approval in the United States last year.
The company says that production at the BioReal facility can be expanded rapidly. The plan is to double current production capacity.
Advertisement
Advertisement
Advertisement
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
Garden of Life Enters the Clear Whey Protein Category with a Light Texture, Non-GMO Certified Isolate Formula
2
Two-Year Trial Shows Vitamin K2 Slowed Coronary Artery Calcification Progression
3
Remedy Science Closes $20M Series A to Expand Clinically Developed Product Line
4
Research Spotlights CD38 Inhibition as a Strategy for NAD+ Preservation
5





